Expertise in
16
conditions

Dr. Joel Schlessinger

Dermatology
2802 Oak View Drive, Ste. 100, 
Omaha, NE 
Accepting New Patients
Referral may be required
Before you request
Expertise in
16
conditions
2802 Oak View Drive, Ste. 100, 
Omaha, NE 

Overview

Joel Schlessinger is a Dermatologist practicing medicine in Omaha, Nebraska.

Dr. Schlessinger is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Impetigo, Candida Infection of the Skin, Rosacea, and Familial Chronic Mucocutaneous Candidiasis.

He is actively involved in clinical research, co-authoring 44 peer reviewed articles and participating in 6 clinical trials. Dr. Schlessinger is currently accepting new patients.

Specialties

Dermatology

Licenses

Dermatology in NE

Hospital Affiliations

The Nebraska Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Avera Health
  • HMO
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Denver Health Medical Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Moda Health
  • EPO
  • PPO
MVP Health
  • EPO
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sanford
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
SelectHealth
  • HMO
  • POS
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 29 Less Insurance Carriers -

Locations

Skin Specialists PC
2802 Oak View Drive, Ste. 100, Omaha, NE 68144

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
Enrollment Status: Completed
Publish Date: February 17, 2026
Intervention Type: Drug
Study Drug: NFX-179
Study Phase: Phase 2
A Phase I/II, Observer-blind, Randomised, Placebo-controlled Study to Assess Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)
A Phase I/II, Observer-blind, Randomised, Placebo-controlled Study to Assess Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)
Enrollment Status: Completed
Publish Date: May 08, 2025
Intervention Type: Biological
Study Phase: Phase 2
Effect of Calcipotriol Plus Betamethasone Dipropionate Gel on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to 16 Years, 11 Months) With Scalp and Body Psoriasis
Effect of Calcipotriol Plus Betamethasone Dipropionate Gel on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to 16 Years, 11 Months) With Scalp and Body Psoriasis
Enrollment Status: Completed
Publish Date: March 10, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: August 18, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of LIPO-202 (Salmeterol Xinafoate for Injection) for the Reduction of Submental Subcutaneous Fat
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of LIPO-202 (Salmeterol Xinafoate for Injection) for the Reduction of Submental Subcutaneous Fat
Enrollment Status: Completed
Publish Date: October 20, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

44 Total Publications

Development of a Core Outcome Domain Set for Facial Aging.
Development of a Core Outcome Domain Set for Facial Aging.
Journal: JAMA dermatology
Published: June 17, 2026
Similar Doctors
Expertise in
61
conditions
Dr. Sara E. West
Dermatology
Expertise in
61
conditions
Dr. Sara E. West
Dermatology
Referral may be required
Before you request

Dermatology Specialists Of Omaha LLC

909 N 96th St Ste 201, 
Omaha, NE 
 (4.9 miles away)
402-330-4555
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Sara West is a Dermatologist practicing medicine in Omaha, Nebraska. Dr. West is highly rated in 61 conditions, according to our data. Her clinical expertise encompasses Basal Cell Skin Cancer, Neurocutaneous Melanosis, Familial Atypical Multiple Mole Melanoma Syndrome, and Giant Congenital Melanocytic Nevus. Dr. West is currently accepting new patients.

Expertise in
68
conditions
Expertise in
68
conditions
Referral may be required
Before you request

Braddock Finnegan Dermatology PC

7911 W Center Rd, 
Omaha, NE 
 (5.1 miles away)
402-390-0333
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Mary Finnegan is a Dermatologist practicing medicine in Omaha, Nebraska. Dr. Finnegan is highly rated in 68 conditions, according to our data. Her clinical expertise encompasses Actinic Keratosis, Seborrheic Keratosis, Warts, and Kaposiform Hemangioendothelioma. Dr. Finnegan is currently accepting new patients.

Expertise in
112
conditions
Expertise in
112
conditions
Referral required
Before you request

CHI Health Clinic Dermatology (CUMC - Bergan Mercy)

7710 Mercy Rd, Ste 3000, 
Omaha, NE 
 (5.4 miles away)
402-717-0750
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Christopher Huerter contributes to theCHI Health Better You Blog. Dr. Huerter is highly rated in 112 conditions, according to our data. His clinical expertise encompasses Actinic Keratosis, Gardner-Diamond Syndrome, Autoerythrocyte Sensitivity, and Psoriasis. Dr. Huerter is board certified in Dermatology - American Board Of Dermatology. Dr. Huerter is currently accepting new patients.

Frequently Asked Questions about Dr. Joel Schlessinger

How do I make an appointment with Dr. Joel Schlessinger?

You can book an appointment with Dr. Joel Schlessinger by calling their office at 402-334-7546. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Joel Schlessinger a top-rated expert for Impetigo?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Joel Schlessinger is classified as an Advanced expert for Impetigo, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Joel Schlessinger specialize in?

While Dr. Joel Schlessinger is a Dermatology, they have specific expertise in Impetigo, Candida Infection of the Skin, and Rosacea. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. Joel Schlessinger participate in research or clinical trials?

Yes. Dr. Joel Schlessinger has published 44 articles and abstracts on conditions like Impetigo. You can view a list of Dr. Joel Schlessinger's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Joel Schlessinger accept my insurance?

Dr. Joel Schlessinger accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 402-334-7546 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schlessinger's expertise for a condition
ConditionClose
      View All 16 Advanced Conditions
      View All 82 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile